Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock

Everolimus (EV), a rapamycin analogue mTOR inhibitor, is used in the clinic to treat Estrogen positive (ER(+)) breast cancer in order to avoid the resistance to hormonotherapy. Here, we investigated whether EV efficacy varied according to administration timing by using the ER(+) breast cancer cell l...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Cycle
Hlavní autoři: Zhang, Yuan, Giacchetti, Sylvie, Parouchev, Alexandre, Hadadi, Eva, Li, Xiaomei, Dallmann, Robert, Xandri-Monje, Helena, Portier, Lucie, Adam, René, Lévi, Françis, Dulong, Sandrine, Chang, Yunhua
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815427/
https://ncbi.nlm.nih.gov/pubmed/29099263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1387695
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky